Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $23.43 Consensus Price Target from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have covered the stock in the last year is $23.43.

A number of research firms have weighed in on CLBT. JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of Cellebrite DI in a research report on Thursday.

Hedge Funds Weigh In On Cellebrite DI

A number of institutional investors have recently modified their holdings of CLBT. Quarry LP bought a new position in Cellebrite DI in the third quarter worth approximately $27,000. Advisors Asset Management Inc. increased its stake in shares of Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after buying an additional 1,742 shares during the period. Gen Wealth Partners Inc bought a new stake in shares of Cellebrite DI in the fourth quarter valued at about $85,000. NewEdge Advisors LLC lifted its stake in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock worth $86,000 after acquiring an additional 3,352 shares during the period. Finally, R Squared Ltd bought a new position in Cellebrite DI during the 4th quarter worth about $100,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

Shares of CLBT opened at $19.46 on Friday. The stock has a market capitalization of $4.66 billion, a price-to-earnings ratio of -14.00, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52. Cellebrite DI has a 1 year low of $10.25 and a 1 year high of $26.30. The business’s 50 day simple moving average is $20.85 and its 200-day simple moving average is $19.89.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, sell-side analysts expect that Cellebrite DI will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.